These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18704955)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.
    Chae SY; Chun YG; Lee S; Jin CH; Lee ES; Lee KC; Youn YS
    J Pharm Sci; 2009 Apr; 98(4):1556-67. PubMed ID: 18704955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
    Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
    Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
    Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.
    Lee S; Youn YS; Lee SH; Byun Y; Lee KC
    Diabetologia; 2006 Jul; 49(7):1608-11. PubMed ID: 16586064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
    Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
    Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation.
    Ma X; Hui H; Liu Z; He G; Hu J; Meng J; Guan L; Luo X
    Diabetes Obes Metab; 2009 Oct; 11(10):953-65. PubMed ID: 19531053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
    Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
    J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
    Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
    Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes.
    Marino MT; Costello D; Baughman R; Boss A; Cassidy J; Damico C; van Marle S; van Vliet A; Richardson PC
    Clin Pharmacol Ther; 2010 Aug; 88(2):243-50. PubMed ID: 20592721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
    Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
    Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.